We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Christopher
Brightling
+44 116 250 2704
abc-3tr@leicester.ac.uk
Miss
Bonnie
Millar
+44 (0)116 252 2893
abc-3tr@leicester.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Severe asthma
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Asthma affects over 350 million people in the world. Approximately 5-10% of people with asthma have severe disease. Asthma is a lung disease associated with inflammation (swelling) of the airways. Certain proteins made by the body, called interleukins, can make this inflammation worse. One of these interleukin proteins is called interleukin- 4Rα (IL4Rα). Interleukin-4Rα appears to play an important role in asthma. It plays a role by helping white blood cells (called eosinophils) stay alive. Eosinophils are involved in the inflammation of the airways. Dupilumab is a medicine that blocks the effect of Interleukin-4Rα on eosinophils (and therefore reduces inflammation). It is given as an injection under the skin and may help reduce inflammation in the airways of people with asthma. Previous research studies in people with severe asthma have shown an improvement in asthma control in those who received dupilumab, and it is now approved for the treatment of severe asthma in the UK. Research studies have shown that people who received dupilumab experienced about half as many asthma exacerbations (severe episodes of asthma or attacks) as those given placebo (dummy) injections. In addition, it also improved their lung function and asthma control. This research study will observe all participants having dupilumab injections as part of their normal clinical care. This will help to understand what might be causing the high levels of disease control, including the absence of symptoms and exacerbations. By doing this, it is hoped that information will be obtained to help improve asthma treatment in the future. The study team will investigate the effect of dupilumab on all aspects of asthma such as changes in quality of life, symptoms, inflammation and breathing tests.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Known hypersensitivity to the active substance of dupilumab or any of the excipients2. Participation in an interventional clinical trial within 3 months of visit 1 or receipt of any investigational medicinal product within 3 months or 5 half-lives. Participation in other observational studies is acceptable if, in the view of the investigator, it will not impact the study outcomes.3. Other clinically significant medical disease or uncontrolled concomitant disease that is likely, in the opinion of the investigator, to require a change in therapy or impact the ability to participate in the study.4. Subjects on regular oral corticosteroids (OCS) and whereby the administration of dupilumab for OCS reduction will not be included in the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Christopher
Brightling
+44 116 250 2704
abc-3tr@leicester.ac.uk
Miss
Bonnie
Millar
+44 (0)116 252 2893
abc-3tr@leicester.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Leicester and funded by Sanofi.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 55224
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
